Probuphine Approval History
FDA Approved: Yes (First approved May 26, 2016)
Brand name: Probuphine
Generic name: buprenorphine
Dosage form: Implant
Company: Titan Pharmaceuticals, Inc.
Treatment for: Opiate Dependence
Probuphine (buprenorphine) is an opioid partial agonist subdermal implant for the treatment of opioid dependence.
Development History and FDA Approval Process for Probuphine
| Date | Article |
|---|
| May 26, 2016 |  FDA Approves Probuphine (buprenorphine) Implant for Treatment of Opioid Dependence |
| Feb 19, 2016 | Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine |
| Jan 12, 2016 | Titan Pharmaceuticals And Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval Of Probuphine |
| Sep 28, 2015 | Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of NDA for Probuphine |
| Jun 8, 2015 | Titan Pharmaceuticals Reports Positive Results from Phase 3 Study of Probuphine for Opioid Addiction |
| Jul 21, 2014 | Titan Pharmaceuticals Announces First Patient Enrollment In Clinical Study Of Probuphine for Opioid Dependence |
| May 1, 2013 | Titan Pharmaceuticals Receives Complete Response Letter From the FDA for Probuphine New Drug Application |
| Feb 27, 2013 | Titan Pharmaceuticals Announces Date of FDA Advisory Committee Review of Probuphine for the Treatment of Opioid Dependence |
| Oct 29, 2012 | Titan Pharmaceuticals Announces Submission of New Drug Application for Probuphine for the Treatment of Opioid Dependence |
| Oct 13, 2010 | Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine Data |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
